News

pharmaphorum23h
MSD adds new indication for Welireg in rare tumours
MSD's oral HIF-2 alpha inhibitor Welireg has a third FDA approval, becoming the first oral treatment for a rare form of solid ...
New Atlas7d
Low blood sugars (as well as high) cause blindness in diabetics
High blood sugars have long been known to cause eye damage in diabetics. However, new research has found that low blood sugar ...
Pharmabiz3h
Merck’s Welireg receives US FDA approval to treat locally advanced, unresectable or metastatic pheochromocytoma or paraganglioma
Rahway, New Jersey Friday, May 16, 2025, 13:00 Hrs [IST] ...
Business Wire22d
Arcus Biosciences to Present First Combination Data for HIF-2a Inhibitor Casdatifan Plus Cabozantinib in an Oral Presentation at the 2025 ASCO Annual Meeting
By selectively binding HIF-2⍺, casdatifan is designed to shut down hypoxic oncogenesis, which blocks tumor growth and key oncogenic pathways, leading to cancer cell death. Clear cell RCC (ccRCC ...
GEN - Genetic Engineering and Biotechnology News8d
Vision Loss in Diabetic Mice Promoted by Hypoglycemia, Treated with HIF Inhibitors
Low blood sugar contributes to eye damage and vision loss in diabetic retinopathy; an experimental drug may help treat the ...
Experimental drug blocks protein that links low blood sugar to diabetic vision loss
In a new study led by scientists at the Wilmer Eye Institute, Johns Hopkins Medicine researchers say they have determined ...